Treatment of AIDS-Related Cutaneous Kaposi's Sarcoma With Topical Alitretinoin (9-cis-Retinoic Acid) Gel

Walmsley, Sharon; Northfelt, Donald W.; Melosky, Barbara; Conant, Marcus A.; Friedman‐Kien, Alvin E.; Wagner, Bridget K.

doi:10.1097/00126334-199911010-00004

Cited by 76 publications

(39 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…251 These include radiation, 252,253 electron beam, 254 photodynamic therapy, 255,256 liquid nitrogen, 257 intralesional vinca alkaloids, [258][259][260][261][262] intralesional interferon-a, 263,264 intralesional human chorionic gonadotropin, 265 and topical 9-cis-retinoic acid gel (alitretinoin). 266 The use of antiviral agents with activity against HHV-8 has also been considered as a therapeutic alternative. 267 Ganciclovir may have activity in vivo against KS.…”

Section: Treatmentmentioning

confidence: 99%

Cutaneous malignancy and human immunodeficiency virus disease

Wilkins

Turner

Dolev

et al. 2006

Journal of the American Academy of Dermatology

129

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Cutaneous malignancy and human immunodeficiency virus disease

Wilkins

Turner

Dolev

et al. 2006

Journal of the American Academy of Dermatology

129

View full text Add to dashboard Cite

“…AIDS-KS is known to be responsive to HAART, and control of HIV load is the primary goal in the treatment of AIDS-KS [46]. Pain, edema and cosmetic concerns arising even from slowly progressive disease can be addressed with local therapies, such as irradiation [47,48] or excision, alitretinoin gel (a retinoid approved for topical application) [49], IFN-α [50], or experimental therapies [51], such as novel angiogenesis inhibitors (reviewed in [46,[52][53][54]). Advanced or quickly progressing disease can be treated with systemic cytotoxic chemotherapy.…”

Section: Kaposi's Sarcoma Therapymentioning

confidence: 99%

Functional Genomics and the Development of Pathogenesis-Targeted Therapies for Kaposi‘s Sarcoma

2005

View full text Add to dashboard Cite

Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.

show abstract

“…Topical 9-cis-retinoic acid (alitretinoin, Panretin ® , Ligand Pharmaceuticals Inc.) gel has recently been licensed for use in patients with cutaneous KS and has been associated with a response rate of up to 50% [77]. Intralesional chemotherapy with vincristine (Oncovin ® , Clonmel Healthcare Ltd) or vinblastine (Velbe ® , Clonmel Healthcare Ltd) gives complete or partial response rates of 60 to 90% in cutaneous lesions, while a second series of injections is often necessary [26,78].…”

Section: Topical Gel and Intralesional Chemotherapymentioning

confidence: 99%

Therapeutic options for human herpesvirus-8/Kaposi’s sarcoma-associated herpesvirus-related disorders

Aoki¹,

Tosato²

2004

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus infection is associated with three proliferative disorders in immunocompromised patients - Kaposi's sarcoma, primary effusion lymphoma and multicentric Castleman's disease. These disorders often develop in patients with advanced AIDS who present a number of therapeutic challenges, underscoring the importance of continuing efforts dedicated to basic and clinical research in this field. In the era of highly active antiretroviral therapy, the incidence of AIDS and Kaposi's sarcoma has considerably decreased, presumably due to enhanced anti-Kaposi's sarcoma-associated herpesvirus immune responses, whereas the situation with primary effusion lymphoma and multicentric Castleman's disease is more complex. Based on advances in the understanding of Kaposi's sarcoma-associated herpesvirus-related disorders and availability of antiretroviral agents, current and future therapeutic approaches will be discussed.

show abstract

Treatment of AIDS-Related Cutaneous Kaposi's Sarcoma With Topical Alitretinoin (9-cis-Retinoic Acid) Gel

Abstract: The results show that alitretinoin gel application is safe and generally well tolerated, and they indicate the superiority of alitretinoin 0.1% gel over vehicle gel in the treatment of cutaneous AIDS-related KS lesions.

Cited by 76 publications

References 35 publications

Cutaneous malignancy and human immunodeficiency virus disease

Cutaneous malignancy and human immunodeficiency virus disease

Functional Genomics and the Development of Pathogenesis-Targeted Therapies for Kaposi‘s Sarcoma

Therapeutic options for human herpesvirus-8/Kaposi’s sarcoma-associated herpesvirus-related disorders

Contact Info

Product

Resources

About